© 2020 MJH Life Sciences and HCPLive. All rights reserved.
Geriatrics
Anti-VEGF Injections Associated with Cognitive Impairment in AMD Patients
July 28, 2020
Article
Interim findings from a cross-sectional study shows a correlation between worse cognitive scoring and a greater rate of intravitreal injections.
Anti-VEGF Treat-and-Extend Regimen Benefits nAMD through Six Years
July 27, 2020
Article
A new analysis of a trio of intravitreal agents show maintained visual acuity in treatment-naive patients for at least 5 years.
Improving Ophthalmology Screening and Telemedicine
July 27, 2020
Video
The specialty is on the precipice of advancement. What gets it over the hurdle?
Mixed Results in Ongoing Brolucizumab Study for nAMD
July 27, 2020
Article
A large proportion of nAMD patients treated with anti-VEGF therapies continue to have active disease and fluid.
What Is the Cross-Specialty Collaboration for Retina Disease?
July 26, 2020
Video
A look at how the specialty functions in telemedicine, and how it could work better with primary care physicians and endocrinologists.
The Burdens of Nonproliferative Diabetic Retinopathy
July 26, 2020
Video
How the condition affects both the vision and mindset of patients, and what clinical outcomes for anti-VEGF research do to address it.
How Diabetics Progress to Retina Complications
July 25, 2020
Video
A look at how primary care patients begin to present with diabetic retinopathy risk.
Annual Alzheimer Disease Pipeline Shows Rapid Progress in Clinical Research
July 24, 2020
Article
As of February, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.
Cataract Surgery Increases Risk of Diabetic Retinopathy
July 20, 2020
Article
Cataracts and diabetic retinopathy are the 2 leading causes of acquired blindness worldwide.
Insufficient Data to Accurately Monitor Most At-Risk Communities for Flu
July 11, 2020
Article
It is important to understand how and why disease risk and health burden vary by socioeconomic status.